|
Welcome
|
|
11 February 2012
|
|
|
| home | my details | ISRCTN Register | mRCT | links | information | press |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
| [ Print-friendly version ] |
| The safety and efficacy of CCX354-C in subjects with rheumatoid arthritis |
| ISRCTN | ISRCTN50655730 |
| ClinicalTrials.gov identifier | NCT01027728 |
| Public title | The safety and efficacy of CCX354-C in subjects with rheumatoid arthritis |
| Scientific title | A randomised, double-blind, placebo-controlled, phase I/II study to evaluate the safety and efficacy of CCX354-C in subjects with rheumatoid arthritis |
| Acronym | CARAT-1 |
| Serial number at source | CL003_354 |
| Study hypothesis |
CCX354-C is safe and well tolerated in subjects with stable rheumatoid arthritis (RA) based on subject incidence of adverse events.
As of 08/03/2010 this record was updated to include a new study site in Romania. Details of this have been added to the country of recruitment field. |
| Lay summary | |
| Ethics approval |
1. Belgium: Comite d'ethique Hospitalo-Facultaire Universitaire de Liege approved on the 30th October 2009 (ref: 2009/200)
Added 15/03/2010: 2. Romania: National Ethic Commission for the Clinical Studies of Medicine approved on the 3rd December 2009 (ref: 3243,3863) |
| Study design | Randomised double-blind placebo-controlled phase I/II study |
| Countries of recruitment | Belgium, Romania |
| Disease/condition/study domain | Rheumatoid arthritis |
| Participants - inclusion criteria |
1. Male or female subjects, aged 18 - 75 years inclusive, with stable RA based on American College of Rheumatology (ACR) criteria for at least 3 months (subjects do not need to have active RA for Stage A of the study)
2. Subjects must have been on a stable dose of methotrexate (7.5 to 25 mg/week) taken orally, subcutaneously, or intramuscularly, but not intravenously, for greater than or equal to 8 weeks prior to randomisation 3. If a subject is also taking sulfasalazine or hydroxychloroquine, the subject must have been on a stable dose of these medications for at least 8 weeks prior to randomisation 4. If a subject is on corticosteroid therapy, the dose must not exceed 10 mg prednisone or equivalent and the subject must have been on a stable dose for at least 4 weeks prior to randomisation 5. Willing and able to give written Informed Consent and to comply with the requirements of the study protocol 6. Negative result of the human immunodeficiency virus (HIV) screen, the hepatitis B screen, and the hepatitis C screen 7. Judged to be otherwise healthy by the Investigator, based on medical history, physical examination (including electrocardiogram [ECG]), and clinical laboratory assessments 8. Female subjects of childbearing potential, and male subjects with partners of childbearing potential, may participate if adequate contraception is used during, and for at least the four weeks after, any administration of study medication. Adequate contraception is defined as usage by at least one of the partners of a barrier method of contraception, together with usage by the female partner, commencing at least three months prior to screening, of a stable regimen of any form of hormonal contraception or an intra-uterine device. Use of abstinence alone is not considered adequate. Use of a barrier method alone is considered adequate only if the male partner was vasectomized at least six months prior to Screening. Use of a double-barrier method of contraception is acceptable. |
| Participants - exclusion criteria |
1. Diagnosed with RA prior to 16 years of age
2. Women who are pregnant, breastfeeding, or have a positive serum pregnancy test at Screening 3. History within one year prior to randomisation of illicit drug use 4. History of alcohol abuse at any time in the past 5. Use of infliximab, adalimumab, abatacept, certolizumab, golimumab, or tocilizumab within 8 weeks of randomisation 6. Use of leflunomide within 6 months of randomisation 7. Use of etanercept or anakinra within 4 weeks of randomisation 8. Use of rituximab or ocrelizumab, or cytotoxic agents, such as cyclophosphamide or chlorambucil, within one year of randomisation 9. Currently taking cytochrome P450 inhibitors including protease inhibitors such as ritonavir, indinavir, nelfinavir, or macrolide antibiotics such as erythromycin, telithromycin, clarithromycin, or azole antifungals such as fluconazole, ketoconazole, itraconazole, or cimetidine, nefazodone, bergamottin (constituent of grapefruit juice), quercetin, aprepitant, or verapamil 10. History or presence of any form of cancer within the 10 years prior to randomisation, with the exception of excised basal cell or squamous cell carcinoma of the skin, or cervical carcinoma in situ or breast carcinoma in situ that has been excised or resected completely and is without evidence of local recurrence or metastasis 11. Evidence of tuberculosis based on chest X rays, tuberculin skin test, QuantiFERON®-TB Gold test, or T-SPOT®.TB test performed during screening 12. Presence of Felty's syndrome, psoriatic arthritis, or other auto-immune diseases 13. Major surgery (including joint surgery) within 12 weeks prior to randomisation 14. Subject's haemoglobin is less than 11 g/dL (6.83 mmol/L) at screening 15. Subject has any evidence of hepatic disease; aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, or bilirubin greater than 1.5 x the upper limit of normal 16. Subject has any evidence of renal impairment; serum creatinine greater than 1.5 x upper limit of normal 17. The subject had an infection requiring antibiotic treatment within 4 weeks of randomisation 18. History or presence of any medical or psychiatric condition or disease, or laboratory abnormality that, in the opinion of the Investigator, may place the subject at unacceptable risk for study participation and may prevent the subject from completing the study 19. Participated in any clinical study of an investigational product within 30 days prior to randomisation |
| Anticipated start date | 08/12/2009 |
| Anticipated end date | 30/03/2010 |
| Status of trial | Completed |
| Patient information material | Not available in web format, please use the contact details below to request a patient information sheet |
| Target number of participants | 24 |
| Interventions |
1. 100 mg CCX354-C or placebo once daily for 14 days
2. 100 mg CCX354-C or placebo twice daily for 14 days 3. 200 mg CCX354-C or placebo once daily for 14 days Total duration of treatment: 14 days Total duration of follow-up: 14 days |
| Primary outcome measure(s) | Subject incidence of adverse events over 14 days of dosing |
| Secondary outcome measure(s) | Evaluate possible interaction with methotrexate at a number of dose levels in subjects with stable RA; pharmacokinetic (PK) measurements on Day 14 and 15. |
| Sources of funding | ChemoCentryx, Inc. (USA) |
| Trial website | |
| Publications | |
| Contact name | Mr Vittorio Marchesin |
| Address |
850 Maude Avenue
Mountain View |
| City/town | California |
| Zip/Postcode | 94043 |
| Country | United States of America |
| vmarchesin@chemocentryx.com | |
| Sponsor | ChemoCentryx, Inc. (USA) |
| Address |
850 Maude Avenue
Mountain View |
| City/town | California |
| Zip/Postcode | 94043 |
| Country | United States of America |
| Sponsor website: | http://www.chemocentryx.com |
| Date applied | 11/12/2009 |
| Last edited | 15/03/2010 |
| Date ISRCTN assigned | 19/02/2010 |
|
|
|
|
|
| © 2012 ISRCTN unless otherwise stated. | |
|
|
|
|